Isopto®-Dex

Dexamethasone, the active ingredient in Isopto-Dex, is a corticosteroid presented as a 0.1% w/v ophthalmic suspension for ocular (topical) use. It treats postoperative ocular inflammation, uveitis, and anterior segment inflammation in patients requiring anti‑inflammatory therapy.

GNH USA supplies Isopto-Dex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isopto-Dex, a topical corticosteroid, is used to manage inflammatory conditions of the anterior eye segment.

Postoperative ocular inflammation: reduces swelling, pain and redness after eye surgery. Uveitis: controls intra‑ocular inflammation and helps prevent tissue damage. Anterior segment inflammation: alleviates redness, edema and discomfort in conditions such as iritis.

Common Side Effects: - Eye irritation or burning sensation. - Transient increase in intra‑ocular pressure. - Blurred vision. - Tearing or watery eyes. - Foreign body sensation. - Conjunctival hyperemia.

Serious or Rare Side Effects: - Cataract formation with prolonged use. - Secondary ocular infection (bacterial, fungal, or viral). - Glaucoma due to sustained pressure elevation. - Delayed wound healing after ocular surgery. - Retinal detachment (very rare).

Before using Isopto-Dex, consider the following precautions.

Monitor intra‑ocular pressure: schedule regular IOP checks during therapy. Avoid use in active viral eye infections: may worsen the condition. Use cautiously in patients with a history of glaucoma. Do not wear contact lenses while administering the suspension. Discontinue if signs of ocular infection appear. Store at room temperature: keep in the original container, protect from light and moisture.

Isopto-Dex may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Systemic corticosteroids: additive systemic glucocorticoid effects. - Antifungal eye drops: may reduce antifungal efficacy.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: potential increase in intra‑ocular pressure. - Beta‑blocker eye drops: possible additive ocular hypotensive effect. - Live vaccines: systemic immunosuppression could diminish vaccine response.